The methemoglobinemia secondary to hemolysis in G6PD-deficient patients poses therapeutic challenges due to the lack of equally effective therapeutic options and the relatively long time to establish G6PD status, which may also result in false negatives in acute hemolysis. The gene discussed is G6PD; the disease is methemoglobinemia.